Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects

被引：98
|
作者：
Kiaie, Seyed Hossein [1 ,2 ,3 ]
Majidi Zolbanin, Naime [4 ,5 ]
Ahmadi, Armin [6 ]
Bagherifar, Rafieh [2 ]
Valizadeh, Hadi [7 ]
Kashanchi, Fatah [8 ]
Jafari, Reza [9 ]
机构：
[1] ReNAP Therapeut, Dept Formulat Dev, Tehran, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Kerman Univ Med Sci, Nano Drug Delivery Res Ctr, Kermanshah, Iran
[4] Urmia Univ Med Sci, Expt & Appl Pharmaceut Sci Res Ctr, Orumiyeh, Iran
[5] Urmia Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Orumiyeh, Iran
[6] Univ Alabama, Dept Chem Mat Engn, Huntsville, AL 35899 USA
[7] Tabriz Univ Med Sci, Drug Appl Res Ctr, Fac Pharm, Tabriz, Iran
[8] George Mason Univ, Sch Syst Biol, Lab Mol Virol, Discovery Hall Room 182,10900 Univ Blvd, Manassas, VA 20110 USA
[9] Urmia Univ Med Sci, Cellular & Mol Med Inst, Cellular & Mol Res Ctr, Orumiyeh, Iran
来源：
JOURNAL OF NANOBIOTECHNOLOGY | 2022年 / 20卷 / 01期
关键词：
Lipid nanoparticles; mRNA delivery; Immunogenicity; Pharmacologic response; Dendritic cell; Immune system; Toll-like receptor; SOLID LIPID NANOPARTICLES; IN-VIVO; CATIONIC LIPIDS; GENE DELIVERY; CANCER-IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; SYSTEMIC DELIVERY; IMMUNE-RESPONSES; DENDRITIC CELLS; DRUG-DELIVERY;
D O I：
10.1186/s12951-022-01478-7
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials.
引用
收藏
页数：20
相关论文
共 50 条
  • [31] Synergistic integration of mRNA-LNP with CAR-engineered immune cells: Pioneering progress in immunotherapy
    Chen, Zhaozhao
    Shu, Jinhui
    Hu, Yu
    Mei, Heng
    MOLECULAR THERAPY, 2024, 32 (11) : 3772 - 3792
  • [32] Esterase-Labile Quaternium Lipidoid Enabling Improved mRNA-LNP Stability and Spleen-Selective mRNA Transfection
    Zhang, Runnan
    Shao, Shiqun
    Piao, Ying
    Xiang, Jiajia
    Wei, Xuyong
    Zhang, Zhen
    Zhou, Zhuxian
    Tang, Jianbin
    Qiu, Nasha
    Xu, Xiao
    Liu, Yanpeng
    Shen, Youqing
    ADVANCED MATERIALS, 2023, 35 (46)
  • [33] Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
    Vaca, Gabriela Baldeon
    Meyer, Michelle
    Cadete, Ana
    Hsiao, Chiaowen Joyce
    Golding, Anne
    Jeon, Albert
    Jacquinet, Eric
    Azcue, Emily
    Guan, Chenxia Monica
    Sanchez-Felix, Xavier
    Pietzsch, Colette A.
    Mire, Chad E.
    Hyde, Matthew A.
    Comeaux, Margaret E.
    Williams, Julie M.
    Sung, Jean C.
    Carfi, Andrea
    Edwards, Darin K.
    Bukreyev, Alexander
    Bahl, Kapil
    SCIENCE ADVANCES, 2023, 9 (38)
  • [34] An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus
    Tian, Yuxin
    Li, Mengjun
    Yang, Yang
    Li, Chunhui
    Peng, Yun
    Yang, Haiyin
    Zhao, Mengyuan
    Wu, Pengfei
    Ruan, Shaobo
    Huang, Yuanyu
    Shen, Chenguang
    Yang, Minghui
    CHINESE CHEMICAL LETTERS, 2024, 35 (08)
  • [35] mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance
    Svensson, Malin
    Limeres, Maria Jose
    Zeyn, Yanira
    Gambaro, Rocio C.
    Islan, German A.
    Berti, Ignacio Rivero
    Ghazi, Silvia Fraude-El
    Pretsch, Leah
    Hilbert, Katja
    Schneider, Paul
    Kaps, Leonard
    Bros, Matthias
    Gehring, Stephan
    Cacicedo, Maximiliano L.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2025, 33 (01)
  • [36] Novel Ionizable Lipids Derived from 2-Hydroxypropylamine and Spermine for mRNA-LNP Delivery
    Lubinus, Ariadna
    Pisano, Joseph
    Belcher, Elizabeth
    Rohde, Christopher B.
    Angel, Matthew
    MOLECULAR THERAPY, 2023, 31 (04) : 599 - 599
  • [37] ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model
    Daly, Owen
    Mahiny, Azita Josefine
    Majeski, Sara
    McClintock, Kevin
    Reichert, Julia
    Boros, Gabor
    Szabo, Gabor Tamas
    Reinholz, Jonas
    Schreiner, Petra
    Reid, Steve
    Lam, Kieu
    Lepper, Marlen
    Adler, Melanie
    Meffen, Tracy
    Heyes, James
    Kariko, Katalin
    Lutwyche, Pete
    Vlatkovic, Irena
    BIOMEDICINES, 2023, 11 (06)
  • [38] Assessing the particle concentration of mRNA-LNP using VIDEODROP : a new parameter to evaluate during LNP process optimization, production and useful for standardization
    Berger, M.
    Ciganek, I.
    Delehedde, C.
    Counil, C.
    Ador, T.
    Delalande, A.
    Pichon, C.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A319 - A319
  • [39] Development of a mRNA Lipid Nanoparticle (mRNA-LNP) Cancer Vaccine to Prevent Leukemia Relapse after Stem Cell Transplant
    Snow, Anson
    Lin, Lin
    Hunsucker, Sally A.
    Wang, Ying
    Liu, Rihe
    Armistead, Paul M.
    BLOOD, 2022, 140 : 7382 - 7383
  • [40] Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects
    Kim, Kyeong Min
    Hwang, Na-Hee
    Hyun, Ja-Shil
    Shin, Dongyun
    MOLECULES, 2024, 29 (10):
12345